23 April 2020
THURSDAY, April 23, 2020 (HealthDay News) -- Accelerated approval has been granted to Trodelvy (sacituzumab govitecan-hziy) to treat patients with metastatic triple-negative breast cancer who have received at least two previous therapies, the U.S. Food and Drug Administration announced Wednesday.
Approval of Trodelvy, a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate, was based on clinical trial data from 108 breast cancer patients with metastatic triple-negative disease. Researchers found an overall response rate of 33.3 percent and a median response duration of 7.7 months. Response was maintained for six months or longer in 55.6 percent of patients who responded, and 16.7 percent of those who responded maintained response for one year or longer.
A Boxed Warning...
22 April 2020
WEDNESDAY, April 22, 2020 (HealthDay News) -- If your diet consists mostly of processed meats, starches and sugary snacks, you may run the risk of developing dementia, a new study suggests.
"How foods are consumed, not only the quantity consumed, may be important for dementia prevention," said lead researcher Cecilia Samieri, a senior researcher in epidemiology at the University of Bordeaux in France.
In other words, it's the total combination of foods, or "network," that may be damaging, she and her team discovered.
Dementia was more common among folks who ate mostly processed meats like ham and sausages, starches like potatoes, and snacks such as cookies and cakes. People without dementia were more likely to eat a diverse diet that included fruits, vegetables, seafood and...
21 April 2020
TUESDAY, April 21, 2020 (HealthDay News) -- Young adults may be waiting too long to seek help for eating disorders, a new study suggests.
Researchers surveyed 300 young adults, ages 18-25, in Australia. They found the majority had eating, weight or body shape concerns.
"Concerningly, only a minority of people with eating disorder symptoms had sought professional help and few believed they needed help despite the problems they were experiencing," said study co-author Dan Fassnacht. He's a psychology lecturer at Flinders University in Adelaide, South Australia.
Reasons for not getting professional care include denial, concerns about losing control of their eating or weight, and not understanding the severity of their eating disorder.
Feeling embarrassed or fearing that others don't...
20 April 2020
MONDAY, April 20, 2020 (HealthDay News) -- The U.S. Food and Drug Administration announced Friday the approval of Tukysa (tucatinib) in combination with trastuzumab and capecitabine for treatment of advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer.
Tukysa, a kinase inhibitor, is indicated for patients who have already received treatment with at least one anti-HER2-based regimen in the metastatic setting. Approval was based on results of the HER2CLIMB clinical trial, which enrolled 612 patients with HER2-positive advanced unresectable or metastatic breast cancer who had previously received treatment with trastuzumab, pertuzumab, and ado-trastuzumab emtansine (T-DM1). Forty-eight percent of patients had brain metastases at trial...